PDF(Pubmed)
Abstract：
Immunotherapy represents an innovative approach to cancer treatment, based on activating the body\'s own immune system to combat tumor cells. Among various immunotherapy strategies, dendritic cell vaccines hold a special place due to their ability to activate T-lymphocytes, key players in cellular immunity, and direct them to tumor cells. In this study, the influence of dendritic cells processed with tumor-derived vesicles on the viability of melanoma cells in vitro was investigated. Dendritic cells were loaded with tumor-derived vesicles, after which they were used to activate T-cells. The study demonstrated that such modified T-cells exhibit high activity against melanoma cells, leading to a decrease in their viability. Our analysis highlights the potential efficacy of this approach in developing immunotherapy against melanoma. These results provide new prospects for further research and the development of antitumor strategies based on the mechanisms of T-lymphocyte activation using tumor-derived vesicles.
摘要：
免疫疗法代表了癌症治疗的创新方法，基于激活人体自身的免疫系统来对抗肿瘤细胞。在各种免疫治疗策略中，树突状细胞疫苗由于其激活T淋巴细胞的能力而具有特殊的地位，细胞免疫的关键角色，并引导它们进入肿瘤细胞。在这项研究中,研究了用肿瘤来源的囊泡处理的树突状细胞对黑色素瘤细胞体外活力的影响。树突状细胞装载肿瘤来源的囊泡，之后，它们被用来激活T细胞。研究表明，这种修饰的T细胞对黑色素瘤细胞表现出高活性，导致其生存能力下降。我们的分析强调了这种方法在开发针对黑色素瘤的免疫疗法中的潜在功效。这些结果为基于肿瘤来源的囊泡激活T淋巴细胞的机制的进一步研究和抗肿瘤策略的开发提供了新的前景。
